A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

Also called NCT06202079

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 179 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06202079
Other papers using this trial's data
  • Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial Metabolism: clinical and experimental, 2026-06 DOI, PubMed 41833659

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06202079. Randomized; no masking; primary purpose treatment. Start 2023-08-11 (actual); primary completion 2024-07-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
GZR4 Injection
Intervention (Drug)
Insulin Degludec
Lead sponsor
Gan and Lee Pharmaceuticals, USA (class: industry)

Record details

Record id
cardio:ct-nct06202079
Content hash
6e7d26c5bcea0ec7fc8ac985aebf1db8c3002b4350f90f9b968c8c1041070df1